Generics maker Alvogen eyes faster growth after CVC-led buyout

Tracy Staton A group of investment funds has teamed up to buy generics maker Alvogen. A consortium led by CVC Capital Partners snapped up a majority stake in the NJ-based company, in ...

Novartis nixes another $600M buyout deal for Gamida Cell

John Carroll Novartis won't be pulling the trigger on a $ 600 million buyout deal for Israel's Gamida Cell after all. Elbit Imaging, the majority owner of a minority stakeholder ...

Bavarian Nordic quashes talk of interest in a Big Pharma buyout

Nick Paul Taylor Bavarian Nordic has downplayed its interest in becoming the latest European biotech to be scooped up by a deep-pocketed suitor. The vaccine player has regained some ...

Endo sews up $9.2B financing for Par Pharma buyout

Carly Helfand Earlier this week, Endo inked a pact to nab Par Pharmaceutical for $ 8 billion. But to do that, it'll need a loan, and it's agreed to a $ 9.275 billion loan ...

Gilead jumps into epigenetics with a bite-size biotech buyout

Damian Garde As market watchers wonder whether Gilead Sciences is on the verge of a blockbuster buyout, the Big Biotech inked a small deal that will beef up its efforts in the growing ...

Hospira CEO Ball stands to reap $80M on Pfizer buyout

Eric Palmer When Hospira's proxy was filed last year, CEO F. Michael Ball's $ 9.9 million in total compensation didn't even rank him among the top 15 highest paid biopharma ...

Roche boosts its antibody arsenal with a $489M buyout

Damian Garde Roche is betting big on antibodies that can attack two targets at once, signing on to buy Austria's Dutalys for as much as $ 488.8 million and get its hands on some ...

Actavis ready to thwart Valeant with $60B-plus Allergan buyout: Bloomberg

Carly Helfand Heads up, Valeant. Actavis is reportedly in talks to snatch up Allergan–and word is it could happen quickly. FiercePharma News

WSJ: Salix inventory issues helped scuttle Allergan buyout

Carly Helfand At one time, Allergan was so confident it could lock up an acquisition of Salix Pharmaceuticals to thwart Valeant's hostile bid that it reportedly snubbed potential ...

AstraZeneca builds cancer R&D dream house with $150M Definiens buyout, J&J deal

John Carroll FierceBiotech News

LabCorp bags Covance, diversifying into CRO biz with $6.1B buyout

John Carroll LabCorp is diversifying. The big diagnostics player has swooped in to buy the contract research organization Covance for $ 6.1 billion in cash and stock, confident that ...

New-drug sales boost plus OTC buyout yields $53B forecast for Bayer

Carly Helfand Bayer is already coasting along sales-wise, with some powerhouse new drugs helping it beat analysts' third-quarter forecasts. And those sales will only keep on growing, ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS